Viking Therapeutics (VKTX) Misses Q1 EPS by 2c

Go back to Viking Therapeutics (VKTX) Misses Q1 EPS by 2c

Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

April 28, 2021 4:05 PM EDT

SAN DIEGO, April 28, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2021, and provided an update on its clinical pipeline and other corporate developments.

... More